Read + Share
Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with
primary biliary cholangitis. J Hepatol 2022 Mar 30. pii: S0168-8278(22)00187.
PMID: 35367282
|
 |
|
Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with
primary biliary cholangitis. J Hepatol 2022 Mar 30. pii: S0168-8278(22)00187.
PMID: 35367282
|
|
|
|